Roth Capital Expects Lower Earnings for Tenax Therapeutics

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Investment analysts at Roth Capital lowered their Q1 2025 EPS estimates for Tenax Therapeutics in a research note issued on Wednesday, March 26th. Roth Capital analyst J. Aschoff now expects that the specialty pharmaceutical company will post earnings of ($0.19) per share for the quarter, down from their previous forecast of ($0.18). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.79) EPS, FY2028 earnings at $1.99 EPS and FY2029 earnings at $3.27 EPS.

Other analysts have also recently issued research reports about the company. StockNews.com began coverage on Tenax Therapeutics in a research report on Friday, March 21st. They issued a “sell” rating for the company. Leerink Partners set a $20.00 target price on shares of Tenax Therapeutics in a research note on Monday, March 10th. Finally, William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday, March 10th. One investment analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Price Performance

Shares of Tenax Therapeutics stock opened at $6.18 on Friday. Tenax Therapeutics has a 1-year low of $2.77 and a 1-year high of $7.89. The company’s fifty day simple moving average is $6.43 and its 200-day simple moving average is $5.40. The stock has a market capitalization of $24.50 million, a PE ratio of -1.16 and a beta of 2.20.

Tenax Therapeutics (NASDAQ:TENX) last announced its earnings results on Tuesday, March 25th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.34.

Hedge Funds Weigh In On Tenax Therapeutics

Hedge funds have recently modified their holdings of the stock. Two Sigma Investments LP purchased a new stake in Tenax Therapeutics in the 4th quarter worth $84,000. Sphera Funds Management LTD. bought a new position in Tenax Therapeutics during the third quarter valued at approximately $101,000. Geode Capital Management LLC grew its holdings in Tenax Therapeutics by 32.4% during the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock valued at $151,000 after buying an additional 5,964 shares in the last quarter. Millennium Management LLC bought a new stake in Tenax Therapeutics in the 4th quarter worth approximately $166,000. Finally, Vestal Point Capital LP bought a new position in shares of Tenax Therapeutics during the 3rd quarter valued at approximately $288,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.